Consideration Allocated To Transaction Rights

No definition available.

Name:	rgen_ConsiderationAllocatedToTransactionRights
Namespace Prefix:	rgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Long Lived Assets Held for sale, Estimated Selling Cost

+ References

No definition available.

+ Details

Name:	rgen_LongLivedAssetsHeldForSaleEstimatedSellingCost
Namespace Prefix:	rgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Non Contingent Consideration Being Recognized As Revenue Over Estimated Period Of Performance

+ References

No definition available.

+ Details

Name:	rgen_NonContingentConsiderationBeingRecognizedAsRevenueOverEstimatedPeriodOfPerformance
Namespace Prefix:	rgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Nonrefundable Upfront Cash Payment Under Collaborations Agreement

+ References

No definition available.

+ Details

Name:	rgen_NonrefundableUpfrontCashPaymentUnderCollaborationsAgreement
Namespace Prefix:	rgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payment To Be Received Upon Signing Of Agreement

+ References

No definition available.

+ Details

Name:	rgen_PaymentToBeReceivedUponSigningOfAgreement
Namespace Prefix:	rgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage Of Future Milestone Payments

+ References

No definition available.

+ Details

Name:	rgen_PercentageOfFutureMilestonePayments
Namespace Prefix:	rgen_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential Additional Milestone Payments Associated With Potential Regulatory Approvals

+ References

No definition available.

+ Details

Name:	rgen_PotentialAdditionalMilestonePaymentsAssociatedWithPotentialRegulatoryApprovals
Namespace Prefix:	rgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Provision For Wholesale Refunds

+ References

No definition available.

+ Details

Name:	rgen_ProvisionForWholesaleRefunds
Namespace Prefix:	rgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

+ Details

Name:	us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rgen_TechnologyTransferMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rgen_ClinicalResearchMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rgen_FirstCommercialSaleMilestoneEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MajorCustomersAxis=rgen_BiomarinPharmaceuticalIncorporatedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=rgen_AssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rgen_TechnologyTransferPaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue Recognition - Additional Information (Detail) - USD ($)			1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 03, 2014	Jan. 30, 2014	Sep. 30, 2014	Jun. 30, 2015	Mar. 31, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue recognized						$ 2,115,000
Non-refundable up-front payment						2,000,000
Payment to be received upon signing of agreement						125,675
Revenue recognized under revenue recognition, up front payment					$ 2,000,000
Royalty and other revenue							$ 1,991,166
Technology Transfer
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue recognized							$ 0
Estimated selling price				$ 300,000		300,000
Consideration allocated to transaction				11,000		11,000
Royalty and other revenue			$ 125,675
Clinical Development
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Milestone Payment						60,000,000
Potential milestone payments to be received				60,000,000		60,000,000
Initial Commercial Sales
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Potential milestone payments to be received				100,000,000		100,000,000
BioMarin Pharmaceutical, Inc. \| Asset Purchase Agreement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Upfront payment received under purchase agreement		$ 2,000,000
Potential milestone payments to be received				160,000,000		160,000,000
Provision for refund						0
Revenue recognized				$ 0		$ 0		$ 2,100,000
BioMarin Pharmaceutical, Inc. \| Clinical Development \| Asset Purchase Agreement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Percentage relate to clinical development from Milestone payment						37.00%
BioMarin Pharmaceutical, Inc. \| Initial Commercial Sales \| Asset Purchase Agreement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Percentage relate to clinical development from Milestone payment						63.00%
BioMarin Pharmaceutical, Inc. \| Technology Transfer Payments \| Asset Purchase Agreement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Milestone Payment	$ 125,675